AUTL

Autolus Therapeutics (AUTL)

About Autolus Therapeutics (AUTL)

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Details

Daily high

$1.67

Daily low

$1.58

Price at open

$1.59

52 Week High

$2.80

52 Week Low

$1.10

Market cap

433.8M

Dividend yield

0.00%

Volume

214,686

Avg. volume

4.1M

P/E ratio

-1.93

Autolus Therapeutics News